Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/6808
Title: | High-dose DTIC in advanced soft-tissue sarcomas in the adult | Authors: | Buesa, J.M. Mouridsen, H.T. van Oosterom, A.T. Verweij, J. Wagener, T. Steward, W. Poveda, A. Vestlev, P.M. Thomas, D. SYLVESTER, Richard |
Issue Date: | 1991 | Source: | Annals of oncology, 2. p. 307-309 | Abstract: | Forty-four of 50 adult patients with advanced soft-tissue sarcoma who had received previous chemotherapy were evaluable for response after treatment with DTIC. The therapeutic schedule consisted of DTIC 1.2 g/m2 infused over 20 minutes, and repeated every 3 weeks. There were 1 complete and 7 partial remissions (objective activity 18%, 95% C.I. 7%-29%), with a median duration of 8 weeks (range 5–19), with the complete remission lasting 1 yr. Hematologic toxicity was dose-limiting; W.H.O. 3 values were observed for WBC in 36%, and for platelets in 26% of patients. The non-hematologic toxicity included nausea and vomiting (90%), a flu-like syndrome (49%), diarrhea (35%), pain in the infused vein (28%) and hypotensive episodes (4%). Intermittent high-dose DTIC is active in advanced soft-tissue sarcoma and should be considered for inclusion in combination regimens. | Document URI: | http://hdl.handle.net/1942/6808 | Link to publication/dataset: | http://annonc.oxfordjournals.org/cgi/content/abstract/2/4/307?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=sylvester&searchid=1&FIRSTINDEX=0&volume=2&issue=4&resourcetype=HWCIT | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.